250 related articles for article (PubMed ID: 17273998)
1. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer.
Wu TC
Eur J Immunol; 2007 Feb; 37(2):310-4. PubMed ID: 17273998
[TBL] [Abstract][Full Text] [Related]
2. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccines for the treatment of cervical cancer.
Sin JI
Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
[TBL] [Abstract][Full Text] [Related]
4. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
5. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
8. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
9. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines.
Einstein MH
Cancer Immunol Immunother; 2008 Apr; 57(4):443-51. PubMed ID: 18157723
[TBL] [Abstract][Full Text] [Related]
10. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
12. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
[TBL] [Abstract][Full Text] [Related]
13. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
14. Preventive and therapeutic HPV vaccines.
Monie A; Hung CF; Wu TC
Curr Opin Investig Drugs; 2007 Dec; 8(12):1038-50. PubMed ID: 18058574
[TBL] [Abstract][Full Text] [Related]
15. [Prophylactic and therapeutic vaccination against human papillomavirus].
Brun JL; Riethmuller D
J Gynecol Obstet Biol Reprod (Paris); 2007 Nov; 36(7):631-41. PubMed ID: 17822860
[TBL] [Abstract][Full Text] [Related]
16. HPV vaccines: the beginning of the end for cervical cancer.
Leggatt GR; Frazer IH
Curr Opin Immunol; 2007 Apr; 19(2):232-8. PubMed ID: 17293100
[TBL] [Abstract][Full Text] [Related]
17. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
18. [Papillomavirus vaccines now allowed--ethical and logistical considerations].
Höpfl R
J Dtsch Dermatol Ges; 2007 May; 5(5):349-52. PubMed ID: 17451379
[No Abstract] [Full Text] [Related]
19. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cervical cancer: where immunology meets diagnostics.
Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
